Summary
Pfizer Inc.'s 2020 10-K report highlights a significant transformation into a focused, innovative biopharmaceutical company following the spin-off of its Upjohn business into Viatris and the formation of the Consumer Healthcare JV. The company experienced revenue growth of 2% year-over-year, reaching $41.9 billion, driven by strong performance in key products like Vyndaqel/Vyndamax and Eliquis, despite an estimated $700 million unfavorable impact from the COVID-19 pandemic. Pfizer's research and development efforts remain robust, with notable progress in its COVID-19 vaccine program in collaboration with BioNTech, which received Emergency Use Authorization (EUA) in multiple countries by the end of 2020. The company's strategic focus on innovation, pipeline advancement, and business development is evident through various collaborations and its commitment to addressing unmet medical needs. While facing typical industry pressures such as pricing and reimbursement challenges and patent expirations, Pfizer's diversified portfolio and strong cash flow position it for continued growth and value creation for shareholders.
Financial Highlights
57 data points| Revenue | $41.65B |
| Cost of Revenue | $8.48B |
| Gross Profit | $33.17B |
| SG&A Expenses | $11.60B |
| Operating Income | $6.63B |
| Interest Expense | $1.45B |
| Net Income | $9.16B |
| EPS (Basic) | $1.65 |
| EPS (Diluted) | $1.63 |
| Shares Outstanding (Basic) | 5.55B |
| Shares Outstanding (Diluted) | 5.63B |
Key Highlights
- 1Revenue increased by 2% to $41.9 billion in 2020, with an operational increase of 3%, despite an estimated $700 million unfavorable impact from the COVID-19 pandemic.
- 2Completed the spin-off and combination of the Upjohn Business with Mylan to create Viatris, transforming Pfizer into a more focused innovative biopharmaceutical company.
- 3The Pfizer-BioNTech COVID-19 vaccine (BNT162b2) received EUA in the U.S. in December 2020 and has been authorized in over 50 countries, with projected revenues of approximately $15 billion in 2021.
- 4Key products like Vyndaqel/Vyndamax, Eliquis, Ibrance, and Xtandi demonstrated strong operational revenue growth.
- 5Research and Development expenses increased by 12% to $9.4 billion, largely due to collaboration costs for the COVID-19 vaccine and upfront payments for new development programs.
- 6The company's financial position remains strong, with $14.4 billion in net cash flow from operations and $1.8 billion in cash and cash equivalents as of December 31, 2020.
- 7Significant business development activities included collaborations with BioNTech, Valneva, CStone, and Myovant, strengthening its pipeline and market position.